Liquid Biopsy Market Analysis: Projected 26% CAGR by 2028, Exploring Size, Share, and Future Growth
Ngày đăng: 09-06-2023 |
Ngày cập nhật: 09-06-2023
MarkNtel Advisors has recently published "Liquid Biopsy Market Analysis Share, Growth, Demand, Forecast 2028," a comprehensive research report that provides in-depth analysis of various factors driving the industry's growth across different geographic regions. This report offers reliable insights into the historical, current, and projected trends, in the Liquid Biopsy Market, presented through detailed explanations, tables, and figures. It equips stakeholders with valuable knowledge of the industry dynamics, enabling them to strategize effectively before making investment decisions.
The report indicates that the Liquid Biopsy Market is anticipated to experience a CAGR of approximately 26% during the period of 2023-2028. Our analysis encompasses a thorough examination of various environmental factors, economic and social issues, technological advancements, and other relevant aspects that are crucial for stakeholders during decision-making processes. In order to provide a reliable, accurate, and comprehensive understanding of the industry, our analysts have conducted extensive research utilizing tools such as SWOT (Strengths, Weaknesses, Opportunities, and Threats) analysis and Porter's Five Forces Analysis.
Get Your Complimentary Sample Report Now! https://www.marknteladvisors.com/query/request-sample/global-5g-infrastructure-market.html
Market Dynamics
Key Driver: Global Surge in Cancer Cases
The number of cancer cases has surged significantly on a global scale. Environmental factors are the leading causes of cancer. The rise in cancer diagnosis has led various countries and international health organizations to undertake various initiatives to spread awareness about cancer. With this increase, Liquid biopsy is preferred for its multiple advantages, counting low-cost, early prognosis, tumor heterogeneity identification, drug resistance, therapeutic drug monitoring, and the most ascendant, patient comfort by eliminating the need for surgery. Consecutively, this increase in preference for Liquid Biopsies is expected to increase the Market during the forecasting period.
Recent Developments
The Liquid Biopsy Market, characterized by its fragmented nature and numerous subdivisions, is thoroughly examined in the report. We provide detailed insights on each segment and geographical location, empowering stakeholders and industry leaders to comprehend the market dynamics and devise new strategies and investments. Furthermore, by gaining a deeper understanding of the ebb and flow within each segment, investors can make well-informed decisions and expand their production and revenue streams in the coming years. The report focuses on key market dynamics, including recent developments, trends, demand and supply chain analysis, purchase patterns, and product/service pricing, among others, within the following segments:
Based on Work Process
- Sample Preparation
- Library Preparation
- Sequencing
- Data Analysis
Based on Technology
- PCR
-- RT-PCR
-- dPCR
-- Multiplex PCR
-- Others
- NGS
- FISH
- Other Technologies
Based on Usage
- RUO
- Clinical
Based on Sample Type
- Blood
- Urine
- Saliva
- Cerebrospinal Fluid
Based on Products
- Test /Services
- Kits and Consumables
- Instruments
Based on Circulating Biomarkers
- Circulating Tumor Cells
- Cell-free DNA
- Circulating Cell-Free RNA
- Exosomes and Extracellular Vesicles
- Others
Based on Disease Type
- Lung Cancer
- Breast Cancer
- Prostate Cancer
- Colorectal Cancer
- Melanoma
- Other Cancers
- Non-Oncology Disorders
Based on Clinical Application
- Treatment Monitoring
- Prognosis and Recurrence Monitoring
- Treatment Selection
- Diagnosis and Screening
Geographically, the Liquid Biopsy Market expands across the following:
- North America
- South America
- Europe
- Middle East & Africa
- Asia-Pacific
Immerse Yourself in the Complete Report: Explore Extensive Research, Market Segmentation, and Competitive Landscape Analysis - https://www.marknteladvisors.com/research-library/global-5g-infrastructure-market.html
Unveiling the Competitive Landscape: Insights into Key Players in the Liquid Biopsy Market 2023-2028
The report provides a comprehensive competitive analysis, highlighting a key aspect of the industry—the existing players. Each player is extensively profiled, covering vital aspects such as business overview, demand and supply chain, key strategies, latest news, product launches, pricing catalog, recent developments, revenue generation, stakes and investments, and trends. These insights aim to assist stakeholders in diversifying and strategizing their investments and participation in the Liquid Biopsy Market, ultimately seeking substantial revenue generation over the forecasted years.
- Bio-Rad Laboratories
- Biocept Inc
- Abcodia Ltd
- Chronix Biomedical
- Epic Sciences Inc
- Hoffmann-La Roche AG
- Cynvenio Biosystems, Inc.
- GUARDANT HEALTH, INC
- Illumina, Inc.
- NeoGenomics Laboratories, Inc.
- Menarini Silicon Biosystems, Inc.
- Qiagen N.V.
- Thermo Fisher Scientific
- Personal Genome Diagnostics, Inc.
- Qiagen N.V.About MarkNtel Advisors
MarkNtel Advisors is a leading research, consulting, & data analytics firm that provides an extensive range of strategic reports on diverse industry verticals. We deliver data to a substantial & varied client base, including multinational corporations, financial institutions, governments, & individuals, among others.
Our specialization in niche industries & emerging geographies allows our clients to formulate their strategies in a much more informed way and entail parameters like Go-to-Market (GTM), product development, feasibility analysis, project scoping, market segmentation, competitive benchmarking, market sizing & forecasting, & trend analysis, among others, for 15 diverse industrial verticals. Using such information, our clients can identify attractive investment opportunities & strategize their moves to yield higher ROI (Return of Interest) through an early mover advantage with top-management approaches.
*For further information, kindly contact our sales team, and allow us to guide your purchase and customization queries.
Media Representative
Email: sales@marknteladvisors.com
Phone: +1 628 895 8081 +91 120 4268433,
Address: 5214F Diamond Heights Blvd #3092,
San Francisco, CA 94131, United States
The report indicates that the Liquid Biopsy Market is anticipated to experience a CAGR of approximately 26% during the period of 2023-2028. Our analysis encompasses a thorough examination of various environmental factors, economic and social issues, technological advancements, and other relevant aspects that are crucial for stakeholders during decision-making processes. In order to provide a reliable, accurate, and comprehensive understanding of the industry, our analysts have conducted extensive research utilizing tools such as SWOT (Strengths, Weaknesses, Opportunities, and Threats) analysis and Porter's Five Forces Analysis.
Get Your Complimentary Sample Report Now! https://www.marknteladvisors.com/query/request-sample/global-5g-infrastructure-market.html
Market Dynamics
Key Driver: Global Surge in Cancer Cases
The number of cancer cases has surged significantly on a global scale. Environmental factors are the leading causes of cancer. The rise in cancer diagnosis has led various countries and international health organizations to undertake various initiatives to spread awareness about cancer. With this increase, Liquid biopsy is preferred for its multiple advantages, counting low-cost, early prognosis, tumor heterogeneity identification, drug resistance, therapeutic drug monitoring, and the most ascendant, patient comfort by eliminating the need for surgery. Consecutively, this increase in preference for Liquid Biopsies is expected to increase the Market during the forecasting period.
Recent Developments
- In August 2022, Thermo Fisher Scientific launched the first NGS-based test to support DNA and RNA input.
- In May 2022, Qiagen N.V. launched the therascreen EGFRplus RGQ PCR kit, a new in vitro diagnostic test for sensitive EGFR mutation analysis.
- In June 2021, Personal Genome Diagnostics Inc. announced to launch of an NGS kit solution, Elio plasma complete, for comprehensive blood-based genomic analysis.
The Liquid Biopsy Market, characterized by its fragmented nature and numerous subdivisions, is thoroughly examined in the report. We provide detailed insights on each segment and geographical location, empowering stakeholders and industry leaders to comprehend the market dynamics and devise new strategies and investments. Furthermore, by gaining a deeper understanding of the ebb and flow within each segment, investors can make well-informed decisions and expand their production and revenue streams in the coming years. The report focuses on key market dynamics, including recent developments, trends, demand and supply chain analysis, purchase patterns, and product/service pricing, among others, within the following segments:
Based on Work Process
- Sample Preparation
- Library Preparation
- Sequencing
- Data Analysis
Based on Technology
- PCR
-- RT-PCR
-- dPCR
-- Multiplex PCR
-- Others
- NGS
- FISH
- Other Technologies
Based on Usage
- RUO
- Clinical
Based on Sample Type
- Blood
- Urine
- Saliva
- Cerebrospinal Fluid
Based on Products
- Test /Services
- Kits and Consumables
- Instruments
Based on Circulating Biomarkers
- Circulating Tumor Cells
- Cell-free DNA
- Circulating Cell-Free RNA
- Exosomes and Extracellular Vesicles
- Others
Based on Disease Type
- Lung Cancer
- Breast Cancer
- Prostate Cancer
- Colorectal Cancer
- Melanoma
- Other Cancers
- Non-Oncology Disorders
Based on Clinical Application
- Treatment Monitoring
- Prognosis and Recurrence Monitoring
- Treatment Selection
- Diagnosis and Screening
Geographically, the Liquid Biopsy Market expands across the following:
- North America
- South America
- Europe
- Middle East & Africa
- Asia-Pacific
Immerse Yourself in the Complete Report: Explore Extensive Research, Market Segmentation, and Competitive Landscape Analysis - https://www.marknteladvisors.com/research-library/global-5g-infrastructure-market.html
Unveiling the Competitive Landscape: Insights into Key Players in the Liquid Biopsy Market 2023-2028
The report provides a comprehensive competitive analysis, highlighting a key aspect of the industry—the existing players. Each player is extensively profiled, covering vital aspects such as business overview, demand and supply chain, key strategies, latest news, product launches, pricing catalog, recent developments, revenue generation, stakes and investments, and trends. These insights aim to assist stakeholders in diversifying and strategizing their investments and participation in the Liquid Biopsy Market, ultimately seeking substantial revenue generation over the forecasted years.
- Bio-Rad Laboratories
- Biocept Inc
- Abcodia Ltd
- Chronix Biomedical
- Epic Sciences Inc
- Hoffmann-La Roche AG
- Cynvenio Biosystems, Inc.
- GUARDANT HEALTH, INC
- Illumina, Inc.
- NeoGenomics Laboratories, Inc.
- Menarini Silicon Biosystems, Inc.
- Qiagen N.V.
- Thermo Fisher Scientific
- Personal Genome Diagnostics, Inc.
- Qiagen N.V.About MarkNtel Advisors
MarkNtel Advisors is a leading research, consulting, & data analytics firm that provides an extensive range of strategic reports on diverse industry verticals. We deliver data to a substantial & varied client base, including multinational corporations, financial institutions, governments, & individuals, among others.
Our specialization in niche industries & emerging geographies allows our clients to formulate their strategies in a much more informed way and entail parameters like Go-to-Market (GTM), product development, feasibility analysis, project scoping, market segmentation, competitive benchmarking, market sizing & forecasting, & trend analysis, among others, for 15 diverse industrial verticals. Using such information, our clients can identify attractive investment opportunities & strategize their moves to yield higher ROI (Return of Interest) through an early mover advantage with top-management approaches.
*For further information, kindly contact our sales team, and allow us to guide your purchase and customization queries.
Media Representative
Email: sales@marknteladvisors.com
Phone: +1 628 895 8081 +91 120 4268433,
Address: 5214F Diamond Heights Blvd #3092,
San Francisco, CA 94131, United States
